IT Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on IT Press Releases.

Press releases published on October 24, 2026

Oct. 24, 2026

TGC 2026: 테크두, 실질적 성과 창출에 초점 맞춘 업무용 AI 솔루션 ‘나보스 프로’ 출시

Indeterminate GlobeNewswire

Oct. 24, 2026

TGC 2026: Tec-Do Melancarkan Navos Pro untuk AI for Work Berorientasikan Hasil

Indeterminate GlobeNewswire

Oct. 24, 2026

TGC 2026: Tec-Do Lança Navos Pro, IA Voltada para Resultados no Trabalho

Indeterminate GlobeNewswire

Oct. 24, 2026

TGC 2026: Tec-Do เปิดตัว Navos Pro มุ่งพัฒนา AI เพื่อการทำงานที่มุ่งเน้นผลลัพธ์

Indeterminate GlobeNewswire

Oct. 24, 2026

2026 National Poppy Campaign launches with a donation “first” … and stunning mural: Don’t forget to Remember

Indeterminate GlobeNewswire

Oct. 24, 2026

JelluTide Gummies Introduces Jellu Tide Multi-Ingredient Dietary Supplement Formulation

Indeterminate GlobeNewswire

Oct. 24, 2026

Quanta Presents Positive Clinical Combination Data in KRAS G12D-Mutant CRC at ESMO and Highlights Pan-KRAS Progress

Indeterminate GlobeNewswire

Oct. 24, 2026

Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors

Indeterminate GlobeNewswire

Oct. 24, 2026

DEEP Robotics Unveils Five Research Advances in Embodied AI

Indeterminate GlobeNewswire

Oct. 24, 2026

XBiotech gibt die Wahl von Sushma Shivaswamy und Jan-Paul Simard zu Co-Chief Executive Officers bekannt

Indeterminate GlobeNewswire

Oct. 24, 2026

XBiotech annonce la nomination de Sushma Shivaswamy et Jan-Paul Simard aux postes de co-directeurs généraux

Indeterminate GlobeNewswire

Oct. 24, 2026

NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma

Indeterminate GlobeNewswire

Oct. 24, 2026

NANOBIOTIX annonce les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle immunitaires chez des patients atteints de mélanome cutané résistant aux anti-PD-1, en traitement de de…

Indeterminate GlobeNewswire

Oct. 24, 2026

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

Indeterminate GlobeNewswire

Oct. 24, 2026

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

Indeterminate GlobeNewswire

Oct. 24, 2026

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

Indeterminate GlobeNewswire

Oct. 24, 2026

Darolutamidi yhdessä ADT- ja sädehoidon kanssa vähensi 58 prosentilla syövän leviämisen tai kuoleman vaaraa potilailla, joilla on suuri eturauhassyövän uusiutumisen riski

Indeterminate GlobeNewswire

Oct. 24, 2026

Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting

Indeterminate GlobeNewswire

Oct. 24, 2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

Indeterminate GlobeNewswire

Oct. 24, 2026

Yangguang News Launches Global Youth Short Video Campaign “Me, Tang Poetry, and AI”

Indeterminate GlobeNewswire